Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IXHL
Upturn stock ratingUpturn stock rating

Incannex Healthcare Ltd ADR (IXHL)

Upturn stock ratingUpturn stock rating
$0.62
Last Close (24-hour delay)
Profit since last BUY67.57%
upturn advisory
WEAK BUY
BUY since 31 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: IXHL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -40.85%
Avg. Invested days 19
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 19.05M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2.47
52 Weeks Range 0.08 - 3.12
Updated Date 06/29/2025
52 Weeks Range 0.08 - 3.12
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.23

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -20952.04%

Management Effectiveness

Return on Assets (TTM) -76.74%
Return on Equity (TTM) -201.88%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 14183550
Price to Sales(TTM) 194.37
Enterprise Value 14183550
Price to Sales(TTM) 194.37
Enterprise Value to Revenue 144.73
Enterprise Value to EBITDA -5.13
Shares Outstanding 93695400
Shares Floating 28234076
Shares Outstanding 93695400
Shares Floating 28234076
Percent Insiders 26.14
Percent Institutions 8.29

ai summary icon Upturn AI SWOT

Incannex Healthcare Ltd ADR

stock logo

Company Overview

overview logo History and Background

Incannex Healthcare Ltd (IXHL) is a clinical-stage pharmaceutical development company creating novel medicinal cannabis pharmaceutical products and psychedelic therapies for unmet medical needs. Founded relatively recently compared to larger pharma companies, it focuses on innovative therapies.

business area logo Core Business Areas

  • Medicinal Cannabis Products: Development and commercialization of medicinal cannabis products for various conditions such as obstructive sleep apnea, traumatic brain injury, and anxiety disorders.
  • Psychedelic Therapies: Research and development of psychedelic therapies, including psilocybin-assisted psychotherapy, for the treatment of anxiety disorders and other mental health conditions.
  • Drug Delivery Technologies: Developing proprietary drug delivery technologies to improve the bioavailability and efficacy of its pharmaceutical products.

leadership logo Leadership and Structure

Incannex Healthcare Ltd has a board of directors overseeing the company's strategy and operations. The executive management team is responsible for the day-to-day management of the business. The company has a structure typical of a clinical-stage pharmaceutical company, with dedicated teams for research, development, clinical trials, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • IHL-42X (Obstructive Sleep Apnea): A combination drug targeting obstructive sleep apnea. It is currently in Phase 2 clinical trials. Market share data is not publicly available as the product is not yet commercialized. Competitors in the OSA treatment market include ResMed (RMD) and Philips (PHG) with CPAP devices, and various pharmaceutical companies working on alternative therapies.
  • IHL-675A (Inflammatory Conditions): A potential treatment for inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease, combining cannabidiol and hydroxychloroquine. Market share data is not yet available. Competitors include AbbVie (ABBV) with Humira and other biologics for inflammatory diseases.
  • Psilocybin-Assisted Psychotherapy: Developing psilocybin-assisted psychotherapy protocols for anxiety disorders, particularly social anxiety disorder and generalized anxiety disorder. The psychedelic therapy market is emerging, and competitors include COMPASS Pathways (CMPS) and MindMed (MNMD).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The medicinal cannabis and psychedelic therapy sectors are rapidly evolving with increasing acceptance and regulatory changes. The development of new therapies for mental health and sleep disorders has created a multi billion dollar industry.

Positioning

Incannex Healthcare is a relatively small player in the pharmaceutical industry. Its competitive advantage lies in its focus on innovative therapies utilizing medicinal cannabis and psychedelics, targeting unmet medical needs. It is positioned in the high-growth areas of novel therapeutics.

Total Addressable Market (TAM)

The TAM for conditions targeted by Incannex, such as sleep apnea, anxiety disorders, and inflammatory diseases, is estimated to be in the tens of billions of dollars annually. Incannex is targeting niche areas within these markets and aims to capture a portion of this market through its innovative therapies.

Upturn SWOT Analysis

Strengths

  • Innovative therapies utilizing medicinal cannabis and psychedelics
  • Focus on unmet medical needs
  • Proprietary drug delivery technologies
  • Strong intellectual property portfolio (patents pending/granted)

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on clinical trial success
  • Regulatory uncertainty surrounding medicinal cannabis and psychedelics
  • Lack of commercialized products (currently clinical stage)

Opportunities

  • Expanding indications for existing therapies
  • Partnerships and collaborations with larger pharmaceutical companies
  • Regulatory approvals in key markets (e.g., FDA, EMA)
  • Increasing acceptance of medicinal cannabis and psychedelic therapies

Threats

  • Competition from larger pharmaceutical companies with greater resources
  • Clinical trial failures
  • Changes in regulations and legislation regarding medicinal cannabis and psychedelics
  • Development of alternative therapies by competitors

Competitors and Market Share

competitor logo Key Competitors

  • ResMed (RMD)
  • Philips (PHG)
  • AbbVie (ABBV)
  • COMPASS Pathways (CMPS)
  • MindMed (MNMD)

Competitive Landscape

Incannex Healthcare faces stiff competition from established pharmaceutical companies with greater resources and larger market share. Its success depends on differentiating itself through innovative therapies and successful clinical trial outcomes.

Major Acquisitions

APIRx Pharmaceutical USA, LLC

  • Year: 2022
  • Acquisition Price (USD millions): 93.3
  • Strategic Rationale: APIRx is a specialty pharmaceutical company focused on the development of prescription cannabinoid medicines. The acquisition accelerates Incannex's clinical programs.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of its research and development pipeline and securing funding for clinical trials.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its therapies. Analyst estimates vary, with some projecting significant revenue growth if its key therapies are approved.

Recent Initiatives: Recent initiatives include advancing its IHL-42X and IHL-675A programs through clinical trials and expanding its psychedelic therapy research.

Summary

Incannex Healthcare is a clinical-stage biopharmaceutical company focused on innovative cannabis and psychedelic therapies. The company has multiple clinical-stage products with potential for significant growth, but faces risks related to clinical trials and regulatory approvals. Its strengths include a focus on unmet needs and proprietary drug delivery technologies. It needs to watch out for larger pharmaceutical companies that could compete in the same area.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Third-Party Market Research

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Investing in pharmaceutical companies, especially clinical-stage companies, involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Incannex Healthcare Ltd ADR

Exchange NASDAQ
Headquaters Sydney, NSW, Australia
IPO Launch date 2022-03-02
President, CEO & Executive Director Mr. Joel Bradley Latham
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 9
Full time employees 9

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.